trending Market Intelligence /marketintelligence/en/news-insights/trending/vywz5q5tdwlcxcv5bplbta2 content esgSubNav
In This List

Matinas BioPharma CEO steps down; replacement named

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Matinas BioPharma CEO steps down; replacement named

Matinas BioPharma Holdings Inc. appointed Jerome Jabbour as CEO and director, effective March 16.

Roelof Rongen has stepped down as CEO and as a member of the company's board as part of a planned transition. He had served as CEO of the company since July 2013.

Jabbour, who is a co-founder of Matinas, has served as president of the company since March 2016 and as executive vice president and chief business officer since 2013.

Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications.